Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 12/20 | 0.72 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.69 |
| ▸ | SYK | P43405 | 4/20 | 0.62 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | STK17B | O94768 | 1/20 | 0.58 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655635 | 0.94 | BCL6 (0.80) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2103957 | 0.92 | BCL6 (0.71) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2100643 | 0.91 | BCL6 (0.72) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2101082 | 0.91 | BCL6 (0.72) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2102021 | 0.90 | BCL6 (0.71) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2102001 | 0.90 | BCL6 (0.71) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2101829 | 0.89 | BCL6 (0.67) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL2104234 | 0.88 | BCL6 (0.66) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL12439249 | 0.85 | BCL6 (0.71) | BCL6NCOR2SYKAURKASTK17B | |
| SCHEMBL657386 | 0.85 | SYK (0.71) | BCL6NCOR2SYKAURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |